AR and prostate carcinoma: While declining trends in BMD over time have been documented in prostate cancer patients without bone metastases [10–12], the assessment of BMD changes in patients with bone metastases—especially those receiving more potent antiandrogenic therapies, such as androgen-receptor signaling inhibitors (ARSI)—remains less standardized [13].